KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Biomarin Pharmaceutical (BMRN) Short term Debt (2016 - 2024)

Historic Short term Debt for Biomarin Pharmaceutical (BMRN) over the last 15 years, with Q2 2024 value amounting to $494.8 million.

  • Biomarin Pharmaceutical's Short term Debt changed N/A to $494.8 million in Q2 2024 from the same period last year, while for Jun 2024 it was $494.8 million, marking a year-over-year change of. This contributed to the annual value of $493.9 million for FY2023, which is 300126.84% up from last year.
  • As of Q2 2024, Biomarin Pharmaceutical's Short term Debt stood at $494.8 million.
  • In the past 5 years, Biomarin Pharmaceutical's Short term Debt ranged from a high of $494.8 million in Q2 2024 and a low of $15.9 million during Q4 2022
  • Over the past 5 years, Biomarin Pharmaceutical's median Short term Debt value was $64.0 million (recorded in 2022), while the average stood at $225.6 million.
  • Its Short term Debt has fluctuated over the past 5 years, first soared by 364290.0% in 2020, then tumbled by 9158.11% in 2021.
  • Biomarin Pharmaceutical's Short term Debt (Quarter) stood at $374.3 million in 2020, then plummeted by 87.11% to $48.2 million in 2021, then crashed by 66.98% to $15.9 million in 2022, then skyrocketed by 3001.27% to $493.9 million in 2023, then grew by 0.19% to $494.8 million in 2024.
  • Its Short term Debt stands at $494.8 million for Q2 2024, versus $494.4 million for Q1 2024 and $493.9 million for Q4 2023.